In a presentation during the 20th European Congress of Psychiatry in Prague, Mayo Clinic psychiatrists will present a systematic literature review of prazosin in the treatment of nightmares. Researchers investigated 12 prazosin studies, four of which were randomized controlled trials.
"The studies showed the drug was well-tolerated and can take effect rapidly, within days to weeks, and some patients reported a return of nightmares when the course of prazosin was stopped," says Simon Kung, M.D., a Mayo Clinic psychiatrist and principal investigator of the study.
"There's not much available for treating nightmares in terms of medications, so prazosin is a promising option," Dr. Kung says.
He added that the literature review opens the possibility of widening the use of prazosin. "Because of the low side effects of prazosin as reported in these studies, it seems logical to extend the use of prazosin to non-PTSD nightmares."
For people who suffer from PTSD, one of the most distressing effects is the experience of nightmares; in particular, the kinds of dreams that ruin sleep with extremely frightening images of physical or emotional threats. Nightmares can be so severe that they can contribute to alcoholism, substance abuse and suicidal thinking.
One possible cause of nightmare symptoms, such as disrupted sleep, is the development of overstimulated chemical messenger norepinephrine receptors in the central nervous system.
"The thinking is that pharmacologic agents, like prazosin, that block these receptors may be ideal in treating nightmares," Dr. Kung says.
Prazosin is a hypertension medication that's been used, following research that began a decade ago, by some Veterans Administration hospitals to treat PTSD-related nightmares.Other investigators in the study include Maria Lapid, M.D., of the Mayo Clinic Department of Psychiatry and Psychology, and Zelde Espinel M.D., M.P.H., of the Universidad El Bosque, Bogota, Colombia.
Nick Hanson | EurekAlert!
Spread of deadly eye cancer halted in cells and animals
13.11.2018 | Johns Hopkins Medicine
Breakthrough in understanding how deadly pneumococcus avoids immune defenses
13.11.2018 | University of Liverpool
Biochips have been developed at TU Wien (Vienna), on which tissue can be produced and examined. This allows supplying the tissue with different substances in a very controlled way.
Cultivating human cells in the Petri dish is not a big challenge today. Producing artificial tissue, however, permeated by fine blood vessels, is a much more...
Faster and secure data communication: This is the goal of a new joint project involving physicists from the University of Würzburg. The German Federal Ministry of Education and Research funds the project with 14.8 million euro.
In our digital world data security and secure communication are becoming more and more important. Quantum communication is a promising approach to achieve...
On Saturday, 10 November 2018, the research icebreaker Polarstern will leave its homeport of Bremerhaven, bound for Cape Town, South Africa.
When choosing materials to make something, trade-offs need to be made between a host of properties, such as thickness, stiffness and weight. Depending on the application in question, finding just the right balance is the difference between success and failure
Now, a team of Penn Engineers has demonstrated a new material they call "nanocardboard," an ultrathin equivalent of corrugated paper cardboard. A square...
Physicists at ETH Zurich demonstrate how errors that occur during the manipulation of quantum system can be monitored and corrected on the fly
The field of quantum computation has seen tremendous progress in recent years. Bit by bit, quantum devices start to challenge conventional computers, at least...
09.11.2018 | Event News
06.11.2018 | Event News
23.10.2018 | Event News
13.11.2018 | Life Sciences
13.11.2018 | Life Sciences
13.11.2018 | Awards Funding